Vertex Pharmaceuticals (VRTX) Equity Average (2010 - 2026)

Vertex Pharmaceuticals' Equity Average history runs 17 years deep, the most recent figure standing at $19.0 billion for Q1 2026.

• In Q1 2026, Equity Average rose 15.56% year-over-year to $19.0 billion; the TTM figure through Mar 2026 stood at $19.0 billion (up 15.56% YoY), while the FY2025 annual figure was $17.5 billion, up 3.19% from the prior year.
• Equity Average was $19.0 billion for Q1 2026 at Vertex Pharmaceuticals, up from $18.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $19.0 billion in Q1 2026 to a low of $10.5 billion in Q1 2022.
• Historically, Equity Average has averaged $15.5 billion across 5 years, with a median of $16.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 37.25% in 2022, then dropped 8.92% in 2025.
• A 5-year view of Equity Average shows it stood at $13.5 billion in 2022, then grew by 26.54% to $17.0 billion in 2023, then slipped by 6.02% to $16.0 billion in 2024, then grew by 12.31% to $18.0 billion in 2025, then grew by 5.68% to $19.0 billion in 2026.
• The last three Equity Average figures came in at $19.0 billion (Q1 2026), $18.0 billion (Q4 2025), and $17.2 billion (Q3 2025), per Business Quant data.